Oral Non-absorbable Polymer-Deferoxamine Conjugates for Reducing Dietary Iron Absorption.

Area of Science:

• Biomaterials Science
• Gastroenterology
• Pharmacology

Background:

• Hereditary hemochromatosis (HH) is a genetic disorder causing excessive iron absorption and accumulation.
• Current HH management relies on phlebotomy and dietary iron restriction.
• Novel strategies are needed to reduce dietary iron uptake.

Purpose of the Study:

• To develop and evaluate non-absorbable polymer-deferoxamine (DFO) conjugates for reducing dietary iron absorption.
• To assess the safety and efficacy of different sized conjugates in an iron overload mouse model.

Main Methods:

• Synthesis of polymer-DFO conjugates in three sizes (56 nm, 256 nm, 7.4 μm).
• In vitro Caco-2 transwell assays to assess permeability and toxicity.
• In vivo oral gavage in a dietary iron overload mouse model to evaluate GI tract transit, serum ferritin, and liver iron levels.

Main Results:

• Conjugates demonstrated no permeability or significant toxicity in vitro.
• In vivo studies showed conjugates remained in the GI tract for up to 12 hours.
• Nanometer-sized conjugates (56, 246 nm) were more effective at reducing iron levels and accumulation than micron-sized conjugates.

Conclusions:

• Orally administered, nanometer-sized polymer-DFO conjugates are safe and effective at reducing dietary iron absorption.
• These conjugates represent a promising alternative therapeutic strategy for managing hereditary hemochromatosis.